Table I.
Antitumor activity and body weight changes in mice implanted with human non-small cell lung cancer tumors from the cell lines, Lu-99 or PC-9, following treatment with S-1 and the EGFR kinase inhibitor, erlotinib.
| Body weight changed
|
|||||||
|---|---|---|---|---|---|---|---|
| Tumor | Drug (mg/kg) | Treatment | Tumor volumea (mm3, mean ± SD) | TGIb (%) | GDPc (days) | (g, mean ± SD) | (%) |
| Lu-99 | Control | - | 1257±196 | - | 0.0 | 2.5±0.5 | 10.1 |
| S-1 (8.3) | days 1–14 | 728±94 | 42.1 | 3.3 | 1.5±1.4 | 6.0 | |
| Erlotinib (100) | days 1–14 | 747±177 | 40.6 | 2.8 | 0.5±1.2 | 2.3 | |
| S-1 + erlotinib | 563±60e | 55.3 | 7.0 | −3.0±2.5 NS | −13.0 | ||
| PC-9 | Control | - | 661±95 | - | 0.0 | 0.9±0.5 | 3.0 |
| S-1 (10.0) | days 1–14 | 427±20 | 35.4 | 1.6 | −0.09±0.8 | −0.3 | |
| Erlotinib (12.5) | days 1–14 | 289±55 | 56.4 | 8.8 | 0.4±0.9 | 1.6 | |
| S-1 + erlotinib | 218±39e | 67.0 | 10.9 | −0.2±0.6 NS | −0.5 | ||
a
Tumor volume on day 15;
b
tumor growth inhibition ratio on day 15;
c
GDP is the difference in time taken for the RTV to reach 2.0 between the treated and the control groups;
d
relative body weight change between days 0 and 15;
e
overall maximal P<0.05 by closed testing procedure using the Aspin-Welch t-test; NS, overall maximal P>0.05 by closed testing procedure using the Aspin-Welch t-test; EGFR, epidermal growth factor receptor; GDP, growth delay period; RTV, relative tumor volume; S-1, tegafur-gimeracil-oteracil.